Risk of recurrence and survival after relapse in patients with Ewing sarcoma.

Background: The prognosis in patients with relapsed Ewing sarcoma is unfavorable. Our investigation identifies factors predicting for the outcome following relapse.

Procedure: We analyzed type of relapse, time to relapse and overall survival after relapse (OSr) in 714 patients with first recurrence.

The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES).

Background: The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES) was investigated.

Methods: We analyzed 120 patients registered into the European Ewing Tumor Working Initiative of National Groups (EURO-E.W.

Ewing's tumors over the age of 40: a retrospective analysis of 47 patients treated according to the International Clinical Trials EICESS 92 and EURO-E.W.I.N.G. 99.

Background: Ewing's tumors (ET) are rare in patients over the age of 40 years. Published data on presentation, treatment, and clinical outcome are limited.

Patients And Methods: We present a retrospective analysis of data from 47 patients in this age group diagnosed with ET and enrolled in the 2 consecutive trials, EICESS 92 and EURO-E.